UBS Group
SHPH icon

UBS Group’s Shuttle Pharmaceuticals SHPH Stock Holding History

UBS Group’s Portfolio SHPH Stock Details SHPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.85K Sell
567
-628
-53% -$8.51K ﹤0.01% 9024
2025
Q4 		$21.5K Buy
1,195
+1,194
+119,400% +$30.5K ﹤0.01% 7733
2025
Q3 		$28 Sell
1
-336
-100% -$12.6K ﹤0.01% 10087
2025
Q2 		$12.7K Buy
+337
New +$20.2K ﹤0.01% 8730
2025
Q1 		– Sell
-131
Closed -$28.2K – 10675
2024
Q4 		$28.2K Buy
+131
New +$34.1K ﹤0.01% 7651
2024
Q2 		– Sell
-1
Closed -$455 – 10027
2024
Q1 		$455 Buy
+1
New +$842 ﹤0.01% 8549
2023
Q1 		– Hold
0
– -$951 – 10291
2022
Q4 		– Sell
-17
Closed -$82.6K – 10019
2022
Q3 		$156K Buy
+17
New +$692K ﹤0.01% 5322

Other funds holding SHPH

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
KFA
Kelleher Financial Advisors New York $395M AUM 12.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's SHPH Position: Q1 2026 in Review

UBS Group reduced its Shuttle Pharmaceuticals (SHPH) stake by 53% in Q1 2026, selling an estimated $8.51K and leaving 567 shares worth $3.85K. The position accounts for ﹤0.01% of the portfolio, ranked #9024.

UBS Group first reported a position in SHPH in Q3 2022 and has held it in 7 quarters since. The position peaked at $156K in Q3 2022. 8 funds tracked by Wall St. Rank hold SHPH as of Q1 2026.

  • UBS Group held 567 shares of Shuttle Pharmaceuticals worth $3.85K as of Q1 2026.
  • UBS Group sold 628 Shuttle Pharmaceuticals shares in Q1 2026, an estimated $8.51K.
  • Shuttle Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9024 holding.
  • UBS Group first reported a position in Shuttle Pharmaceuticals in Q3 2022 and has held it in 7 quarters since.
  • UBS Group's Shuttle Pharmaceuticals position peaked at $156K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Shuttle Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.